chemieunternehmen.com

Evotec AG announced today that Evotec and Celgene Corporation have entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases. Initial disease areas of focus will include Amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, and multiple other neurodegenerative disorders. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-and-celgene-enter-into-drug-discovery-collaboration-for-neurodegenerative-diseases-5420

Evotec AG today announced that it has made an offer to acquire Cyprotex PLC (AIM Listing: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in UK. The proposed acquisition, which has been unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-ag-announces-its-intent-to-acquire-cyprotex-plc-5626

Evotec AG today announced that, in the context of the half year results published on 10 August 2016, it increases its financial guidance for the current year. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-ag-increases-its-profitability-guidance-for-2016-5378

Evotec AG today announced that it increases its financial guidance for the current year. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/evotec-ag-increases-its-revenue-guidance-for-2015-12

Evotec AG today announced that it is adjusting its guidance regarding Group revenues. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/evotec-ag-results-of-pre-clinical-studies-lead-to-reduction-in-revenues-nevertheless-profitable-and-more-than-eur-90-m-cash-for-2013-confirmed-5612

Hamburg, Germany – 17 December 2012: Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it has entered into a license agreement with Janssen Pharmaceuticals, Inc. … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/evotec-announces-nmda-antagonist-license-agreement-5606

Evotec AG  today announced that it is adjusting its guidance regarding profitability on operating income for the fiscal year 2012. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/shifted-milestone-income-leads-to-reduction-in-operating-income-guidance-for-the-fiscal-year-2012-5603

Evotec AG that Evotec and Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/evotec-and-bayer-enter-into-multi-target-alliance-to-fight-endometriosis-5602

Evotec AG today announced that it has entered into a license and collaboration agreement with Janssen Pharmaceuticals, Inc. with a particular focus on the regeneration of insulin- producing beta cells. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/curebeta-a-collaboration-between-evotec-ag-and-harvard-university-enters-strategic-alliance-with-janssen-pharmaceuticals-5600